PfizerPFE
Briefing quotidien des marchés
Ce briefing n’est pas encore disponible dans cette langue — version anglaise affichée.
Dernier briefing
Pfizer's stock approaches 52-week high after solid Q2 earnings report.
Pfizer Inc. (NYSE: PFE) reported strong second-quarter 2026 results, with revenues of $15.03 billion, a 2.6% increase from the previous year, surpassing analyst expectations. The company's stock is trading near its 52-week high, reflecting investor confidence.
Briefings précédents
Pfizer's stock rises 2.15% to $28.57 amid Q2 earnings beat and raised revenue guidance.
Pfizer's stock price increased by 2.15% to $28.57 following a strong Q2 earnings report and an upward revision of its 2026 revenue guidance. The company reported Q2 revenue of $15.03 billion, surpassing expectations, and raised its full-year revenue guidance midpoint by $500 million.
Pfizer's Q2 2026 earnings beat expectations; stock near 52-week high.
Pfizer reported a 3% increase in Q2 2026 revenue, driven by strong performance in oncology and primary care portfolios. The company raised its full-year revenue guidance midpoint to $61.5 billion, reflecting confidence in its pipeline and non-COVID products. The stock is trading near a 52-week high, indicating positive market sentiment.
Pfizer's stock remains stable near analyst target of $28 following Q2 earnings.
Pfizer's stock price has remained stable near the analyst target of $28 following the release of its Q2 2026 earnings report. The company reported an adjusted earnings per share of $0.77, surpassing analyst expectations of $0.68, and confirmed its full-year 2026 earnings guidance of $2.80 to $3.00 per share. Despite these positive results, the stock's performance has been relatively flat, indicating a neutral market sentiment.
Pfizer's stock remains steady amid legal settlement and 2026 earnings outlook.
In the past 24 hours, Pfizer's stock has maintained stability as investors digest a new Depo-Provera settlement framework and the company's 2026 earnings guidance. The stock closed at $28.07 on August 21, 2026, with an intraday high of $28.42 and a low of $27.65. The market capitalization stands at approximately $159.97 billion, with a P/E ratio of 36.93.
Pfizer's Q2 2026 earnings beat expectations, stock holds gains near $28.
Pfizer's stock remains strong following a Q2 2026 earnings report that exceeded analyst expectations and a raised full-year guidance. The company's focus on oncology projects and institutional investor interest contribute to the positive sentiment.
Pfizer's Q2 earnings beat estimates; $4.3B writedown impacts GAAP EPS.
Pfizer reported strong Q2 earnings, with revenue of $15.03 billion and adjusted EPS of $0.77, surpassing analyst expectations. However, a $4.3 billion noncash impairment charge related to a lung cancer trial setback resulted in a GAAP EPS loss of $0.04. The company also raised its full-year revenue guidance to $60.5–62.5 billion, while reducing its COVID-19 product revenue outlook to approximately $4 billion.
Pfizer's stock rises 3.69% to $28.24 amid positive market sentiment on August 19, 2026.
Pfizer's stock experienced a significant uptick, closing at $28.24 on August 19, 2026, a 3.69% increase from the previous close. This surge aligns with a broader market rally, where major U.S. stock indexes posted modest gains following positive developments, including a measure by the U.S. Treasury Department to ease bond market pressure and strong earnings reports from companies like Estee Lauder and Target.
Pfizer's stock rises 1.45% to $27.25 amid steady market conditions
Over the past 24 hours, Pfizer's stock price has increased by 1.45%, closing at $27.25. This movement aligns with the broader market trend, as no significant company-specific news has emerged during this period.
Pfizer's stock remains stable at $26.87 amid market fluctuations.
Over the past 24 hours, Pfizer's stock price has shown minimal movement, closing at $26.87 on August 17, 2026. This stability reflects a lack of significant market-moving news during this period.
Pfizer's stock price remains steady at $26.79 amid market stability.
Over the past 24 hours, there have been no significant developments affecting Pfizer's stock performance. The stock closed at $26.79 on Friday, August 14, 2026, with minimal intraday fluctuations. Investors are awaiting upcoming events, including the third-quarter 2026 dividend payment scheduled for September 1, 2026.
No significant market-moving news for Pfizer (PFE) in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Pfizer's stock performance. The company continues to focus on its strategic initiatives, including cost-saving measures and expanding its oncology and obesity portfolios. Traders should monitor upcoming earnings reports and industry trends for potential impacts on Pfizer's stock.
Pfizer's Q3 2026 dividend of $0.43 per share declared, payable September 1.
Pfizer's Board of Directors declared a quarterly cash dividend of $0.43 per share for Q3 2026, payable on September 1, 2026, to shareholders of record as of July 24, 2026. This marks the 351st consecutive quarterly dividend paid by the company. No significant market-moving news has been reported in the past 24 hours.
Pfizer's stock rises 1.84% to $26.80 amid steady dividend payouts.
In the past 24 hours, Pfizer's stock price increased by 1.84%, closing at $26.80. This uptick aligns with the company's consistent dividend strategy, with the most recent quarterly dividend of $0.43 per share declared in April 2026.
Pfizer's stock drops 1.18% to $26.31 amid market fluctuations
Pfizer's stock experienced a slight decline of 1.18%, closing at $26.31 on August 12, 2026. This movement reflects broader market trends rather than company-specific news.
Pfizer's Q1 2026 Dividend Declared at $0.43 per Share
Pfizer's Board of Directors has declared a quarterly cash dividend of $0.43 per share for Q1 2026, payable on March 6, 2026, to shareholders of record as of January 23, 2026. This marks the 349th consecutive quarterly dividend paid by the company.
No significant market-moving news for Pfizer (PFE) in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Pfizer's stock performance. The company continues to focus on its strategic initiatives, including cost realignment and expansion into oncology and obesity treatments. Investors are advised to monitor upcoming earnings reports and industry trends for potential impacts on Pfizer's performance.
Pfizer's stock remains steady at $26.76 amid recent developments
Over the past 24 hours, there have been no significant market-moving news regarding Pfizer. The stock closed at $26.76 on August 7, 2026, with a slight increase of $0.55 (2.09%) from the previous close. The intraday high was $26.75, and the low was $26.05. The market capitalization stands at $152.5 billion, with a P/E ratio of 35.21 and an EPS of $0.76.
Pfizer's stock price remains steady at $26.76 amid market stability.
Over the past 24 hours, there have been no significant developments affecting Pfizer's stock performance. The stock closed at $26.76 on August 7, 2026, reflecting market stability. Investors are awaiting upcoming earnings reports and potential regulatory updates for future guidance.
Pfizer's stock (PFE) closes at $26.76, up 2.09% on August 7, 2026.
In the past 24 hours, there have been no significant developments affecting Pfizer's stock performance. The stock closed at $26.76 on August 7, 2026, reflecting a 2.09% increase from the previous close. No major news or events have been reported that would influence the stock's movement.
Pfizer's stock (PFE) closes at $26.20, up 1.51% on August 6, 2026.
In the past 24 hours, there have been no significant developments affecting Pfizer's stock performance. The stock closed at $26.20 on August 6, 2026, marking a 1.51% increase from the previous close. No major news or events have been reported that would influence the stock's movement.
Pfizer's stock price rises 1.5% to $25.81 amid steady market performance
Over the past 24 hours, Pfizer's stock (PFE) has experienced a modest increase of 1.5%, closing at $25.81. This uptick reflects stable market conditions without significant news impacting the company's performance.
Pfizer's stock price rises 1.48% to $25.41 amid steady performance.
In the past 24 hours, Pfizer's stock (PFE) experienced a modest increase of 1.48%, closing at $25.41. This uptick reflects the company's stable market performance, with no significant news or events impacting its stock price during this period.
No significant market-moving news for Pfizer (PFE) in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Pfizer's stock performance. The company continues to focus on its strategic initiatives, including cost-saving measures and expanding its oncology and obesity treatment portfolios. Investors are advised to monitor upcoming earnings reports and industry trends for potential impacts on Pfizer's performance.
No significant market-moving news for Pfizer (PFE) in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Pfizer's stock performance. The company continues to focus on its strategic initiatives, including cost-saving measures and expansion into oncology and obesity treatments. Investors are advised to monitor upcoming earnings reports and industry trends for potential impacts on Pfizer's performance.
Pfizer's Q2 2026 dividend of $0.43 per share declared, payable June 12, 2026.
Pfizer's Board of Directors declared a quarterly cash dividend of $0.43 per share for Q2 2026, payable on June 12, 2026, to shareholders of record as of May 8, 2026. This marks the 350th consecutive quarterly dividend paid by the company.
Pfizer's stock price remains steady at $25.01 amid market stability.
Over the past 24 hours, there have been no significant developments affecting Pfizer's stock performance. The stock closed at $25.01 on July 31, 2026, with minimal intraday fluctuations. Investors are awaiting upcoming earnings reports and potential regulatory updates for future guidance.
Pfizer's Q2 2026 Dividend Declared at $0.43 per Share
Pfizer's Board of Directors has declared a quarterly cash dividend of $0.43 per share for the second quarter of 2026, payable on June 13, 2025, to shareholders of record as of May 9, 2025. This marks the 346th consecutive quarterly dividend paid by the company.
No significant market-moving news for Pfizer (PFE) in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Pfizer's stock performance. The company continues to focus on its strategic initiatives, including cost-saving programs and acquisitions in oncology and obesity treatments. Investors are advised to monitor upcoming earnings reports and industry trends for potential impacts on Pfizer's stock.
Pfizer's stock rises 2.43% to $25.25 amid positive analyst outlook.
Pfizer's stock price increased by 2.43% to $25.25, following positive analyst assessments. RBC Capital upgraded Pfizer's rating to 'Sector Perform' with a $25.00 price target, citing improved valuation and upcoming catalysts. Additionally, the Swiss National Bank increased its stake in Pfizer by 7.1%, now holding approximately 16.7 million shares valued at $468.5 million.
Analysez n’importe quel graphique en quelques secondes
Voici la lecture du jour sur Pfizer. Pointez votre caméra vers n’importe quel graphique et ChartDetector AI vous livre une analyse technique complète en quelques secondes — gratuit sur iOS.
Généré par IA à partir de sources d'actualités publiques. Ceci n'est pas un conseil financier.